GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BI-853520 | BI853520 | IN10018
Compound class:
Synthetic organic
Comment: We mapped the structure for the INN ifebemtinib via PubChem to the research code BI-853520. BI-853520 is a selective, ATP-competitive inhibitor of focal adhesion kinase (FAK), that has anti-tumour effects in preclinical [3,5] and early clinical studies [1-2]. FAK inhibitors enhance effector T cell infiltration into the tumour microenvironment [4].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| BI 853520/IN10018 is being evaluated for anti-tumour potential in solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01335269 | A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer | Phase 1 Interventional | Boehringer Ingelheim | ||
| NCT04109456 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | Phase 1 Interventional | InxMed (Shanghai) Co., Ltd. | ||